With the October 2025 launch of Tyruko (natalizumab), neurologists have now been exposed to three different biosimilar categories, and one has been around since before the COVID-19 pandemic. It’s logical to assume that when a specialty is exposed to biosimilar competition for the first time, acceptance and uptake of the biosimilar might be slow. … Continue reading How Comfortable Are Neurologists With Biosimilar Prescribing?
Copy and paste this URL into your WordPress site to embed
How Comfortable Are Neurologists With Biosimilar Prescribing?
With the October 2025 launch of Tyruko (natalizumab), neurologists have now been exposed to three different biosimilar categories, and one has been around since before the COVID-19 pandemic. It’s logical to assume that when a specialty is exposed to biosimilar competition for the first time, acceptance and uptake of the biosimilar might be slow. … Continue reading How Comfortable Are Neurologists With Biosimilar Prescribing?